Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H 3rd, Venkatakrishnan K, Neuwirth R, Riordan WJ, Karol M, von Moltke LL, Acharya M, Zannikos P, Keith Stewart A. Reece DE, et al. Among authors: keith stewart a. Cancer Chemother Pharmacol. 2011 Jan;67(1):57-67. doi: 10.1007/s00280-010-1283-3. Epub 2010 Mar 20. Cancer Chemother Pharmacol. 2011. PMID: 20306195 Free PMC article. Clinical Trial.
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel P, Fonseca R, Vincent Rajkumar S, Keith Stewart A. Khan ML, et al. Among authors: keith stewart a. Br J Haematol. 2012 Feb;156(3):326-33. doi: 10.1111/j.1365-2141.2011.08949.x. Epub 2011 Nov 23. Br J Haematol. 2012. PMID: 22107129 Free article.
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
Rosenthal A, Dueck AC, Ansell S, Gano K, Conley C, Nowakowski GS, Camoriano J, Leis JF, Mikhael JR, Keith Stewart A, Inwards D, Dingli D, Kumar S, Noel P, Gertz M, Porrata L, Russell S, Colgan J, Fonseca R, Habermann TM, Kapoor P, Buadi F, Leung N, Tiedemann R, Witzig TE, Reeder C. Rosenthal A, et al. Among authors: keith stewart a. Am J Hematol. 2017 May;92(5):467-472. doi: 10.1002/ajh.24693. Epub 2017 Mar 22. Am J Hematol. 2017. PMID: 28230270 Free article. Clinical Trial.
Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma.
Baughn LB, Jessen E, Sharma N, Tang H, Smadbeck JB, Long MD, Pearce K, Smith M, Dasari S, Sachs Z, Linden MA, Cook J, Keith Stewart A, Chesi M, Mitra A, Leif Bergsagel P, Van Ness B, Kumar SK. Baughn LB, et al. Among authors: keith stewart a. Blood Cancer J. 2023 May 22;13(1):84. doi: 10.1038/s41408-023-00851-5. Blood Cancer J. 2023. PMID: 37217482 Free PMC article.
Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma.
Jain T, Dueck AC, Kosiorek HE, Ginos BF, Mayo A, Reeder CB, Chesi M, Mikhael J, Keith Stewart A, Leif Bergsagel P, Fonseca R. Jain T, et al. Among authors: keith stewart a. Am J Hematol. 2016 Dec;91(12):E504-E505. doi: 10.1002/ajh.24548. Epub 2016 Oct 11. Am J Hematol. 2016. PMID: 27581088 Free article. Clinical Trial. No abstract available.
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Zangari M, et al. Among authors: keith stewart a. Eur J Haematol. 2011 Jun;86(6):484-7. doi: 10.1111/j.1600-0609.2011.01602.x. Eur J Haematol. 2011. PMID: 21477075 Free article. Clinical Trial.
11 results